Graphic Era Hospital’s Milestone Treatment of Two Complex Cases

Posted on August 26, 2025 by MaryO
DEHRADUN, 23 August: Graphic Era Hospital has achieved a remarkable mileston by successfully treating two complex cases of the rare hormonal disorder Cushing’s Disease in Dehradun. The hospital’s experts used advanced technology and surgical skills to give the patients a new lease on life, marking this significant achievement.
In the first case, a 27-year-old woman was brought to the Endocrinology Department at Graphic Era Hospital after long-term weight gain, facial puffiness, irregular menstrual cycles, high blood pressure, and kidney stones. Tests and lab reports confirmed that the patient was suffering from ACTH-dependent Cushing’s Syndrome – Pituitary Microadenoma. A 3-Tesla Dynamic Pituitary MRI revealed a 6 mm tumor, while other organs were normal.
The specialists performed surgery using endoscopic trans-nasal neuro-navigation technology, completing it successfully without opening the brain. After the operation, the patient experienced significant weight loss, normalized blood pressure, regular menstrual cycles, and all hormone levels returned to normal.
In the second case, a 24-year-old woman came to Graphic Era Hospital with extremely high blood pressure (200/100), headache, weight gain, and irregular menstrual cycles. MRI revealed a 7–9 mm tumor in an unusual location in the pituitary gland, which was also affecting the pituitary fossa bone. Despite multiple medications, her blood pressure remained uncontrolled, and CT scans showed an impact on her heart.
The multi-specialty team performed surgery using endoscopic trans-nasal neuro-navigation technology, again without opening the brain. After surgery, her blood pressure normalized and her menstrual cycles became regular.
In both cases, pituitary microadenomas were diagnosed. The surgeries were done through the nasal route using microscopes and endoscopes, with neuro-navigation helping to accurately locate the tumors while protecting the pituitary gland. The multi-specialty team included Head of Neurosciences and HOD Neurosurgery Partha P Bishnu, Senior Consultant Neurosurgery Ankur Kapoor, Senior Neurosurgeon and Neurointervention Specialist Payoz Pandey, Senior Consultant ENT Parvendra Singh, Director Endocrinology, Obesity and Diabetes Sunil Kumar Mishra, and the Neuro-Anesthesia Team.
With the latest technology and expert doctors at Graphic Era Institute of Medical Sciences, new milestones continue to be achieved. Previously, the hospital’s expert doctors had successfully implanted pacemakers in the brain, placed a third pacemaker in complex pediatric cases, replaced two heart valves without open-heart surgery, unblocked the esophagus without surgery, and performed open-heart surgery through a small 2.5-inch facial incision without cutting bones. Director of Graphic Era Hospital, Puneet Tyagi,  Mefical Superintendent, Gurdeep Singh Jheetay, Dean SL Jethani and COO Atul Bahl were present at the press conference.

Filed under: Cushing's, pituitary, symptoms, Treatments | Tagged: , , , , , , , , , | Leave a comment »

The Reflex Dexamethasone Suppression Test: Development and Assessment of Reflexed Serum Dexamethasone Measurement for the Diagnosis of Cushing Syndrome

Posted on August 23, 2025 by MaryO

Abstract

Background

Screening for Cushing syndrome (CS; endogenous overproduction of ACTH or cortisol) is performed by the low-dose overnight serum dexamethasone suppression test (oDST) with the measurement of serum dexamethasone concentration to assure an effective dose.

Objective

We evaluated the utility of only measuring serum dexamethasone in samples with nonsuppressed serum cortisol using a conservative serum cortisol cutoff.

Methods

This retrospective study included 261 oDSTs completed before Reflex implementation (Pre-Reflex-oDST) and 281 oDSTs completed after (Post-Reflex-oDST). Serum cortisol and serum dexamethasone data were paired to the diagnosis and analyzed with comparative statistical tests and receiver operating characteristic curve (ROC) analysis.

Results

Endogenous hypercortisolism was diagnosed in 38 of 261 Pre-Reflex-oDSTs (14%) and 40 of 281 (14%) Post-Reflex-oDSTs. In oDSTs with SerCort >1.8 mcg/dL, there were 9% and 6% false positives in the Pre-vs Post-Reflex-oDST group, respectively. In the Pre-Reflex-oDST group, the median SerCort was 1.1 mcg/dL (95% CI: 0.8–1.5) in patients without CS and 3.9 mcg/dL (95% CI: 2.6–7.9) in those with CS (P < 0.001). The optimal ROC cutoff of SerCort in the Pre-Reflex-oDST group was 2.1 mcg/dL (sensitivity 92%, specificity 93%). In the Post-Reflex-oDST group, the median SerCort was 1.1 mcg/dL (95% CI: 0.8–1.5) in patients without CS and 2.9 mcg/dL (95% CI: 2.6–7.9) in those with CS (P < 0.001). The optimal ROC cutoff of SerCort in the Post-Reflex-oDST group was 2.1 mcg/dL (sensitivity 95%, specificity 93%; not different from Pre-Reflex-oDST group).

Conclusion

Reflex measurement of the serum dexamethasone did not affect oDST test performance while reducing costs.

Abbreviations

CS

Cushing syndrome
oDST

low-dose overnight serum dexamethasone suppression test
ROC

receiver operating characteristic
NH

neoplastic hypercortisolism
NNH

non-neoplastic hypercortisolism
HPA

hypothalamic pituitary adrenal
SerCort

serum cortisol
SerDex

serum dexamethasone
WDL

Wisconsin Diagnostic Laboratories
LOQ

limit of quantification
UFC

urine free cortisol

Highlights

  • •
    Reflexing only nonsuppressed serum cortisol samples for the measurement of serum dexamethasone does not negatively affect the performance of the overnight low-dose DST (oDST)
  • •
    Reflex implementation greatly reduced the number of serum dexamethasone measurements thereby decreasing unnecessary costs
  • •
    The oDST appeared to be valid as long as there was a measurable serum dexamethasone result (>50 ng/dL)

Clinical Relevance

We report a novel Reflex overnight dexamethasone suppression test (oDST) serum dexamethasone measurement protocol with the benefit of greatly lowering costs without loss of oDST performance supporting its implementation in screening for Cushing syndrome.

Introduction

Endogenous Cushing syndrome (CS) includes neoplastic hypercortisolism either due to autonomous cortisol production or excessive ACTH secretion.1 Non-neoplastic hypercortisolism (NNH) is also an important clinical entity that is characterized as bona fide cortisol excess caused by conditions such as depression, chronic kidney disease, and poorly controlled diabetes.2, 3, 4 Chronically elevated cortisol levels contribute to significant morbidity and mortality due to cardiovascular, metabolic, musculoskeletal, and immunologic effects, including hypertension, diabetes, osteoporosis, and increased susceptibility to infections5,6 leading to prolonged disease burden and worsening clinical outcomes.2,3
Biochemical evaluation is indicated for individuals presenting with features of hypercortisolism, as well as for those with adrenal incidentalomas, regardless of symptoms, in accordance with current guidelines.7 However, the workup is complicated by varying severities of hypercortisolism and diurnal rhythm of endogenous cortisol requiring screening tests to take advantage of predictable nadirs and negative feedback.1 One of the current first-line screening tests for CS is the 1 mg (low dose) overnight dexamethasone suppression test (oDST).8 Positive oDST results require additional testing such as late-night salivary cortisol and 24 h urine free cortisol measurements.8, 9, 10
The oDST takes advantage of decreased HPA negative feedback sensitivity in CS.11 An oral 1 mg dexamethasone dose is given between 2300 hours and 2400 hours and serum cortisol (SerCort) is then measured at 0800 h the following morning with levels <1.8 mcg/dL (50 nmol/L) representing normal suppression.8 A clinical sensitivity of 95% highlights the oDST as a useful screening tool; however, a specificity of ∼80% indicates a greater potential for false-positive results.10,12 A higher burden of false-positive results complicates diagnosis, leading to further testing, delays in diagnosis and treatment, and increased costs and resource utilization for both patients and the health care system. Therefore, the measurement of a serum dexamethasone (SerDex) in the next morning SerCort sample should identify insufficient SerDex levels that may result from factors such as mistiming of, or altogether missing the dexamethasone dose, differences in dexamethasone metabolism, variation in gastrointestinal absorption, increased cortisol binding globulin (eg, due to oral contraceptives), and medications that alter CYP3A4 activity.13, 14, 15, 16, 17
To reduce unnecessary and costly SerDex measurements, our institution implemented in 2023 a Reflex protocol in which SerDex is only measured if post-oDST SerCort is ≥ 1.6 mcg/dL (ie nonsuppressed). This approach was suggested but not evaluated by Genere et al.18 Since the purpose of this study was not to validate the concept of the oDST, we chose 1.6 mcg/dL as a conservative cutoff so that borderline SerCort with small variations around the accepted 1.8 mcg/dL cutoff would not bias the results. This study assessed equivalency in test performance between Pre- and Post-Reflex-oDST implementation and estimated the associated cost savings. As a secondary outcome, we evaluated therapeutic SerDex levels necessary for valid testing.

Materials and Methods

Study Design

A retrospective cohort study was performed on all oDSTs completed at Froedtert & the Medical College of Wisconsin and the affiliated Wisconsin Diagnostic Laboratories between May 2023 and April 2024. This study was approved by the Medical College of Wisconsin Institutional Review Board as a Quality Improvement Project under PRO00050802. All data in the database were de-identified and coded.

Study Population

The study population included patients aged ≥18 years who completed a oDST in the outpatient setting through the system with serum samples processed through Wisconsin Diagnostic Laboratories. Cohorts were divided into Pre- and Post-Reflex-oDST groups based on the date of Reflex implementation described below (October 31, 2023), with the Pre-Reflex-oDST group consisting of tests performed in the 6 months prior and the Post-Reflex-oDST group including tests from the 6 months following implementation. The ordering clinician still had the option to choose oDST AM cortisol alone without ordering a SerDex measurement. Exclusion criteria included repeat oDST for the same patient within the same 6-month period (Pre- or Post-Reflex-oDST groups); however, results from patients who underwent oDST during both the Pre- and Post-Reflex-oDST periods were included. Patients with SerDex <50 ng/dL were also excluded. At this time, all patients included in the analysis had either a confirmed hypercortisolism diagnosis or were determined not to have pathophysiological hypercortisolism based on clinical and biochemical evaluation.8 A combination of biochemical tests (24-hour free urine cortisol, late-night salivary cortisol, oDST), imaging (adrenal and pituitary CT/MRI), and other testing (DDVAP testing, surgical outcome, biopsy) were used to confirm the diagnosis of CS per the current guidelines.8 Hypercortisolism included both neoplastic causes (CS) and non-neoplastic causes (NNH).2 In our study, NNH included patients with chronic nausea and weight loss, chronic kidney disease, poorly controlled diabetes, excess alcohol intake, obesity with physiological stress, chronic pain, and opioid withdrawal. For simplicity, all hypercortisolism patients are abbreviated “CS” whether neoplastic or non-neoplastic.

Procedures

Patients were instructed to take 1 mg of dexamethasone at 11:00 pm and then had their blood sampled the next morning between 8:00 and 9:00 am SerCort level was measured using the Roche Elecsys Cortisol II Electrochemiluminescence immunoassay performed on a Cobas e801 module.19 In the Pre-Reflex-oDST group, individual orders for serum cortisol and dexamethasone were placed by the provider. Both tests were performed, regardless of the subsequently reported oDST serum cortisol value. In the Post-Reflex-oDST group, a single “Dexamethasone Suppression Cortisol Reflex” order was placed, that prompted a SerCort measurement. If SerCort was ≥1.6 mcg/dL (ie, nonsuppressed), an electronic order for a SerDex send-out measurement was automatically placed by the laboratory information system. The laboratory’s automated processing line removed the serum sample from storage, created an aliquot and placed it in a queue for samples to be sent to ARUP Laboratories. ARUP Laboratories measured SerDex by liquid chromatography-mass spectrometry (limit of quantitation [LOQ] = 50 ng/dL; reference interval: 140 – 295 ng/dL; https://ltd.aruplab.com/Tests/Pub/2003248).

Data Collection

Data acquired from each oDST, including date and time of collection, SerCort, and SerDex, were extracted from the laboratory information system. Additional data, including demographics, CS diagnosis, and treatment were collected from the electronic health record and securely stored in RedCAP (version 15.0.2; Nashville, TN). Patients with inconclusive test results were followed for several months after oDST until a diagnosis was established through additional testing and/or clinical evaluation.

Outcomes Assessment

The primary outcome of this study was to quantify the number of SerDex tests avoided while assessing whether implementation of the Reflex oDST affected overall test performance in the screening for endogenous hypercortisolism. Equivalency between Pre- and Post-Reflex-oDSTs was defined by the similarities in prevalence of a new diagnosis, average SerCort by diagnosis, and SerCort cutoffs by receiver operating characteristic (ROC) curve AUC, and optimal cutoff values. Secondary outcomes included quantification of avoided SerDex measurements to estimate the cost savings associated with Reflex implementation using the US Medicare Reimbursement Rate [20 Accessed 4/1/2025; CPT code 80 299)]. We also evaluated suppressed oDST’s SerDex concentrations to determine if there was a correlation between SerDex level achieved and the degree of suppression of SerCort.

Statistical Analysis

All statistical analyses were performed using Sigmaplot 15.0 (RRID:SCR_003210; https://scicrunch.org/resolver/SCR_003210; Systat Software, Inc, Inpixon, Palo Alto, CA). Continuous variables that were not normally distributed are presented as the median and interquartile ranges. Demographic data were analyzed by two-way analysis of variance and chi-square. Differences in SerCort and SerDex between Pre- and Post-Reflex-oDST groups and CS diagnosis were tested by Mann-Whitney U test and t-test. Optimal cutoff values for each group were determined by ROC analysis using Youden’s index and AUCs were compared with a DeLong test. A P value <0.05 was considered statistically significant. Post-hoc power analyses results are provided where appropriate.

Results

Study Population Characteristics

A total of 616 oDSTs (308 in the Pre-Reflex-oDST and 308 in the Post-Reflex-oDST groups) were screened for eligibility (Fig. 1). After excluding oDSTs with SerDex below the LOQ (n = 12) and repeated oDSTs in the same patient (n = 62), a total of 542 oDSTs were included for analysis. Demographic data are presented in Table 1. The without CS group was younger than the patients with CS group in both Pre- and Post-Reflex-oDST groups. There were no differences in the distribution of race between the groups with and without CS groups and the Pre-vs Post-Reflex-oDST groups. There were more females regardless of diagnosis, but the sex distribution was not different Pre vs Post-Reflex-oDST implementation.

  1. Download: Download high-res image (445KB)
  2. Download: Download full-size image

Figure 1. Flowchart of participants selection from 616 completed oDSTs completed 6 months before (n = 308) and after (n = 308) Reflex implementation. Subsequent oDSTs for the same patient and unmeasurable post-oDST serum dexamethasone (SerDex) (<50 ng/dL [Lower quantifiable limit]) were excluded from analysis. A total of 542 oDSTs were included for analysis and breakdown of CS diagnosis and etiology are shown. ACTH-dependent CS is further broken down to differentiate neoplastic (NH) versus non-neoplastic (NNH) etiologies. CS = Cushing Syndrome; NH = neoplastic hypercortisolism; NNH = nonneoplastic hypercortisolism; oDST = overnight dexamethasone suppression test; SerDex = serum dexamethasone.

Table 1. Demographic Characteristics of Patients Who Underwent oDST Before and After Reflex Implementation

Empty Cell Pre-Reflex Post-Reflex
Yes CS with NNH Yes CS without NNH No CS Yes CS with NNH Yes CS without NNH No CS
N 38 34 223 40 38 241
Age
 Mean (SD) 63.6 (13.8) 63.8 (14.4) 56.0 (15.1)a 63.8 (13.2) 63.1 (13.1) 55.3 (15.5)b
Sex
 Male (%) 6 (15.8) 4 (11.8) 57 (25.6) 11 (27.5) 11 (28.9) 67 (27.8)
 Female (%) 32 (84.2) 30 (88.2) 166 (74.4) 29 (72.5) 27 (71.1) 174 (72.2)
Race
 American Indian or Alaskan Native (%) 0 0 1 (0.4) 0 0 1 (0.4)
 Asian (%) 0 0 3 (1.3) 0 0 1 (0.4)
 Black or African American (%) 5 (13.2) 5 (14.7) 27 (12.2) 6 (15.0) 6 (15.8) 23 (9.5)
 Other (%) 2 (5.3) 1 (2.9) 8 (3.6) 1 (2.5) 1 (2.2) 9 (3.8)
 White (%) 31 (81.5) 28 (82.4) 184 (82.5) 33 (82.5) 31 (82.0) 207 (85.9)
Data are further stratified by Cushing syndrome (CS) diagnosis. Age is presented as mean (SD); sex and race as counts (percentages).
a
Age different from group with CS within Pre-Reflex-oDST (P = 0.005).
b
Age different from group with CS within Post-Reflex-oDST (P < 0.001) regardless of whether NNH cases are included. Male vs female distribution NS (χ2 = 2.533, 3 df, P = 0.469). Race distribution NS (χ2 = 4.37733, 12 df, P = 0.976).
Within the Pre-Reflex-oDST group, 38 patients (14%) were diagnosed with endogenous hypercortisolism (CS) with 13 being ACTH-dependent (9 pituitary and 4 non-neoplastic hypercortisolism) and 25 being ACTH-independent. Within the Post-Reflex-oDST group, 40 patients (14%) were diagnosed with CS with 11 being ACTH-dependent (8 pituitary, 2 non-neoplastic, and 1 ectopic ACTH) and 25 being ACTH-independent.

Prereflex-oDST vs Post-reflex-oDST Analysis

In the Pre-Reflex-oDST group, out of the 261 included subjects, 172 oDSTs (65%) suppressed to <1.6 mcg/dL, meaning that only 89 tests would have undergone reflex SerDex measurements after implementation of Reflex testing. Among these, 51 were determined not to have CS. In the Post-Reflex-oDST group, out of 281 subjects, 191 oDSTs (68%) suppressed to <1.6 mcg/dL, resulting in 90 reflexed SerDex measurements, of which 50 did not have CS. Within the Pre-Reflex-oDST group, there were 38 patients who had CS and in the Post-Reflex-oDST group 40 patients were found to have CS. There was no difference in CS prevalence between the Pre- and Post-Reflex-oDST groups (P = 0.52). Among oDSTs with SerCort levels >1.8 mcg/dL [the conventional cutoff 8], 24/262 (9% false positive) in the Pre-Reflex-oDST group and 21/281 (7% false positive) in the Post-Reflex-oDST group were later determined not to have CS by standard guidelines criteria.8 Reflex implementation resulted in a reduction of the number of SerDex measurements by 68% resulting in cost savings of at least $18.64 per ordered oDST.
In the Pre-Reflex-oDST group, the median SerCort was 1.1 mcg/dL (95% CI: 0.8–1.5) in patients who did not have CS and 3.9 mcg/dL (95% CI: 2.6–7.9) in those who had CS (P < 0.001). In the Post-Reflex-oDST group, the median SerCort was also 1.1 mcg/dL (95% CI: 0.8–1.5) in patients who did not have CS and 2.9 mcg/dL (95% CI: 2.6–7.9) in those who had CS (P < 0.001) (Fig. 2). There was no difference comparing the CS diagnosis status between Pre- and Post-Reflex-oDST groups. There was still no difference in median SerCort in patients with CS when comparing the Pre- and Post-Reflex-oDST groups with NNH cases excluded (P = 0.269). Furthermore, the NNH patients were biochemically indistinguishable from patients with neoplastic hypercortisolism (NH). In fact, when we compared post-oDST cortisol between NH (3.6 [2.4-7.7; N = 72) and NNH (3.4 [2.7-8.5; N = 6]), the P value was 0.729. There was also no difference between CS NH with NNH included vs CS NH excluding NH within the Pre-Reflex-oDST group and within the Post-Reflex-oDST group.

  1. Download: Download high-res image (195KB)
  2. Download: Download full-size image

Figure 2. Comparison of oDST serum cortisol (SerCort) levels Pre-vs Post-Reflex-oDST implementation. The medians are further stratified based on whether the patient did not have Cushing Syndrome (No CS – red) and those who had CS (Yes CS – blue). Each box represents the interquartile range and the horizontal line within represents the median. The error bars represent the 10th-90th percentiles and dots represent results outlying the 10th-90th percentiles. a, denotes significant difference of median SerCort levels between no CS vs CS in both Pre- and Post-Reflex-oDST groups (P < 0.001). There was no difference in medians following exclusion of NNH from Yes CS in both Pre- and Post-Reflex-oDST groups (P = 0.269). CS = Cushing Syndrome; NH = neoplastic hypercortisolism; NNH = nonneoplastic hypercortisolism; oDST = overnight dexamethasone suppression test; SerDex = serum dexamethasone.

A power analysis was performed to compare Pre-reflex oDST to Post-Reflex oDST SerCort values in patients with CS with the null hypothesis that there was no effect of implementing the reflex approach. Assuming a clinically significant effect of implementing the reflex test (a difference of oDST serum cortisol of 2 mcg/dL with a conservative SD of the difference of 2.5 mcg/dL) with sample sizes of 38 Pre-Reflex and 40 Post-Reflex in our study, the power was 0.937 with an alpha of 0.050. With an expected difference in serum cortisol of 0.8 mcg/dL and an SD of the difference of 1.0 mcg/dL, the power was 0.937 with an alpha of 0.05. Considering that the patients before and after reflex implementation were from the same population, institution, and ordering clinicians, we are confident that the Reflex testing did not influence the oDST performance and the laboratory data outcomes.
There was also no difference in SerCort between Pre- and Post-Reflex-oDST tests in the predictive performance for CS. The ROC curve AUC of SerCort in both the Pre- and Post-Reflex periods was 0.97. The optimal ROC cutoff of SerCort in the Pre-Reflex-oDST group was 2.1 mcg/dL (sensitivity 92%, specificity 93%). The optimal ROC cutoff of SerCort in the Post-Reflex-oDST group was 2.1 mcg/dL (sensitivity 95%, specificity 93%; not different from Pre-Reflex-oDST group) (Table 2). When NNH cases were excluded and ROC curves were rerun, there was no difference in ROC curve area, optimal SerCort cutoff values, or sensitivity and specificity in Pre- and Post-Reflex-oDST groups.

Table 2. Receiver operating characteristic (ROC) analysis of oDST SerCort results for Pre-vs Post-Reflex-oDST groups. A. Analysis including NNH patients are at the top; B. Analysis excluding NNH patients are at the bottom

Empty Cell Pre-Reflex Post-Reflex
A. Including NNH patients
 ROC Curve Area (SE) 0.97 (0.01) 0.97 (0.01)
 95% confidence interval 0.96-0.99 0.95-0.99
 P value P < 0.0001 P < 0.0001
 Sample size: No CS/Yes CS 223/38 241/40
Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity
 Optimal 8 AM SerCort Cutoff (mcg/dL) 2.1 92% 93% 2.1 95% 93%
Empty Cell Pre-Reflex without NNH Post-Reflex without NNH
B. Excluding NNH patients
 ROC curve area (SE) 0.97 (0.01) 0.97 (0.01)
 95% confidence interval 0.96-0.99 0.95-0.99
 P Value P < 0.0001 P < 0.0001
 Sample size: No CS/Yes CS 223/34 241/38
Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity
 Optimal 8 AM SerCort Cutoff (mcg/dL) 2.1 91% 92% 2.1 95% 93%
Area under the curve (AUC) was calculated and compared with a DeLong test (AUC = 0.97, P < 0.0001, for both). Using Youden’s Index, optimal cutoff values were determined by maximizing sensitivity and specificity. When ROC rerun without NNH, the sensitivity and specificity did not change in both Pre- and Post-oDST-Reflex groups.

Prereflex-oDST Comparison of SerDex vs SerCort

In comparing the Pre-Reflex-oDST group SerDex results of <140 ng/dL versus >140 ng/dL (the lower reference limit of the SerDex assay), median SerCort was 1.2 mcg/dL and 1.1 mcg/dL, respectively (P = 0.621) (Fig. 3A). The scatter regression plot illustrates that there was no relationship between SerDex (ng/dL) and SerCort (mcg/dL) by CS diagnosis (Fig. 3B). Each point represents an individual oDST, with red indicating patients who did not have CS (n = 223) and blue indicating those who had CS (n = 38). In patients who did not have CS, SerDex ranged from 61.5 to 908.9 ng/dL whereas in patients who had CS, SerDex ranged from 96.3 to 646.0 ng/dL. Theoretical linear regression lines are shown. In fact, no significant correlation between SerDex and SerCort was found in the group who did not have CS (r = 0.002; P = 0.972) nor the group who had CS (r = 0.114; P = 0.494) so the regression lines are only provided for visual clarity. When NNH cases were excluded, there was still no correlation between SerDex and SerCort in patients with CS (P = 0.432). Furthermore, analysis of only NNH cases also showed no correlation between SerDex and SerCort (P = 0.871).

  1. Download: Download high-res image (397KB)
  2. Download: Download full-size image

Figure 3. Comparison of post-oDST serum cortisol (SerCort) to serum dexamethasone (SerDex) in Pre-Reflex-oDST group. (A) Comparison of post-oDST SerCort and SerDex for no CS patients in the Pre-Reflex-oDST group. SerCort in the No CS patients stratified by the ARUP Lower limit of the reference range for SerDex (140 ng/dL). There was no significant difference in median SerCort with the SerDex <140 ng/dL (N = 20) and >140 ng/dL (N = 203) groups (1.2 vs 1.1 mcg/dL, respectively, P = 0.621). (B) Comparison of all Pre-Reflex-oDST group oDSTs stratified by patients with (blue) and without (red) CS. The black vertical solid line represents the limit of quantitation (LOQ) of SerDex (50 ng/dL). There was no correlation of SerDex and SerCort achieved in either group (see text for specifics). There was no correlation when NNH cases were removed as well (P = 0.432). CS = Cushing Syndrome; NH = neoplastic hypercortisolism; NNH = nonneoplastic hypercortisolism; oDST = overnight dexamethasone suppression test; SerDex = serum dexamethasone.

Discussion

The purpose of this study was to assess the usefulness of implementing a protocol to only reflex samples for the measurement of SerDex that do not suppress post-oDST SerCort (the “Reflex-oDST”) using a very conservative 8 AM cortisol cutoff. The major findings were as follows: (a) There was no detrimental effect on oDST-suppressed SerCort levels with the implementation of Reflex testing. That is, the SerCort levels in patients without CS were not different from each other Pre- and Post-Reflex-oDST. The same was found in the group who had CS. (b) There were comparable optimal SerCort ROC cutoff values in the Pre- and Post-Reflex-oDST groups, which also demonstrated a lack of a detrimental effect on test performance. (c) The Reflex protocol eliminated the need for SerDex measurement in 68% of oDSTs ordered without reducing the accuracy of the oDST. (d) No correlation was found between SerCort and SerDex indicating that the SerDex concentration achieved may not be an important factor in assessing the accuracy of the oDST; rather the presence of a detectible SerDex may be sufficient (ie, a Boolean function).
When comparing the Pre- and Post-Reflex-oDST groups, we observed no difference in patient population characteristics, including the prevalence of positive oDSTs, CS diagnosis, and CS etiology. Notably, patients who had CS were older than those who did not have CS in both groups. Ueland et al demonstrated a positive correlation between age and oDST SerCort, which may partially explain the significantly higher age in patients with CS.17 Age-related changes in HPA axis dynamics likely contributed to an increased prevalence of unsuppressed results.21 Additionally, older patients often have more comorbidities, which may lead clinicians to have a lower threshold for further evaluation, increasing the likelihood of identifying CS in this population.
To demonstrate that implementation of oDST Reflex protocol did not negatively affect diagnostic performance, we compared SerCort levels and false positive rates defined by unsuppressed SerCort later determined not to have CS through further testing. We found no difference in SerCort levels before and after implementation of Reflex testing (within the patients who did not have CS and within the patients who had CS). We observed a 7% false positive rate in the Pre-Reflex-oDST group that was comparable to 10% to 14% in previous studies.17,22 We found a comparable 9% false positive rate in the Post-Reflex-oDST group demonstrating preservation of test performance with Reflex implementation. These data are similar to those theorized by Genere et al18 and we have now validated the approach.
Implementation of reflex SerDex testing reduced the number of oDST SerDex measurements by ∼68% and resulted in a cost savings of $18.64 per ordered oDST using Medicare Clinical Diagnostic Laboratory Test reimbursement data, though this likely underestimates the true financial burden as patients are often billed at higher rates.20 Therefore, the Reflex protocol not only did not have a detrimental effect on test performance but also improved efficiency by reducing unnecessary costs and resource utilization. It is also important to point out that the approach is likely to save additional costs like avoiding additional analysis such as unnecessary plasma ACTH, salivary cortisols, UFCs, and even MRIs.
For the purposes of diagnosis of CS, we used accepted oDST SerCort cutoff of ≤1.8 mcg/dL (50 nmol/L) that yields a sensitivity of 95% and a specificity of ∼80%.10,12 We, like most clinicians, utilize a ≤1.8 mcg/dL SerCort diagnostic cutoff with concomitant measurement of SerDex to improve specificity by reducing false positives due to subtherapeutic dexamethasone levels. For the current study, we used the cutoff of 1.6 mcg/dL to determine when to reflex samples for SerDex in the Post-Reflex-oDST group to be as conservative as possible particularly when considering biological variability around a value of 1.8 mcg/dL.
To demonstrate equivalency, we found SerCort cutoff values that maximize specificity based on oDSTs performed similarly in both Pre- and Post-Reflex-oDST groups. Our calculated cutoff value for SerCort Pre- and Post-Reflex-oDST validated that a small increase in SerCort oDST cutoffs results in an increase in specificity to >95% (utilizing Youden’s index). However, given that the oDST is a screening test, sensitivity should be prioritized. While higher specificity reduces false positives, it may also increase the risk of missing mild CS cases. Notably, it has been shown that concomitant SerDex measurement reduces false positives by 20%,17 reinforcing the benefit of its inclusion.
To be conservative, we reanalyzed all of the data excluding the 6 patients with NNH. This had no effect on any of the outcomes. In fact, the oDST 8AM cortisol was almost identical when comparing NH to NNH patients further emphasizing the clinical challenge of distinguishing these highly overlapping groups in terms of their laboratory results.
Similar to previous studies, we found a broad range of SerDex levels across all oDSTs with minimal or no correlation to SerCort.9,23,24 To maximize specificity, Ueland et al proposed a SerDex cutoff value of 130 ng/dL [0.130 mcg/dL (3.3 nmol/L)], while Ceccato et al proposed a SerDex cutoff of 180 ng/dL [0.180 mcg/dL (4.5 nmol/L)] prioritizing specificity.17,25 SerCort levels the morning after taking 1 mg of dexamethasone (8 AM–9 AM) reflects delayed glucocorticoid negative feedback at the pituitary and hypothalamus that takes at least 1-2 h to be fully expressed.26 Therefore, differences in measured SerDex at 8 AM the morning after the 1 mg dose ingestion reflect the variability of HPA axis feedback sensitivity and the timing of the pharmacokinetics of dexamethasone metabolism that can be influenced by several factors, such as age, BMI, and concomitant medications.11,13,27,28 Our findings suggest that any detectible SerDex level (>50 ng/dL in our study), even if below the established reference interval (eg,140–295 ng/dL), is sufficient for a valid test and probably does not require repetition. That said, it may still be prudent to repeat the test if the SerCort does not suppress to <1.8 mcg/dL and the SerDex is < 100 ng/dL particularly with a high index of suspicion for CS.24 oDSTs with SerDex values below the laboratory’s detectable limits (LOQ) should still be considered invalid, most likely due to dexamethasone noncompliance or differences in absorption and/or pharmacokinetics as described above. It is also important to point out that the LOQ for some serum dexamethasone assays are higher than the assay we used, which makes this point even more important.18
An important final point is the practicability of the approach. Why not just store the serum cortisol sample and only test it for serum dexamethasone if requested18? This is very challenging for clinicians in practice who work with a variety of reference laboratories and are often not aware of the SerCort oDST results until after the sample has been discarded. By building the reflex approach into the ordering system, this problem is avoided as it does not require the intervention of the ordering clinician, thereby reducing the administrative burden while reducing laboratory costs. The significance of our novel study is confirmed by the fact that, subsequent to our implementation, a major reference laboratory has recently established a similar Reflex oDST test (https://www.labcorp.com/tests/503990/cortisol-dexamethasone-suppression-test-with-reflex-to-dexamethasone). Others are likely to follow. Our study, which is the first of its kind to our knowledge, should give the clinician assurance that this approach is appropriate. At our relatively small laboratory, this results in annual cost savings of $11,500 per year just for the dexamethasone levels not needed. The savings for each institutional and provider would obviously be different depending on their patient mix and test volumes.

Conclusion

We demonstrated that the implementation of the Reflex protocol avoided unnecessary SerDex measurements without affecting test performance, highlighting its utility from both a resource and cost standpoint. Additionally, our findings suggest that any quantifiable SerDex level, even if below the established reference interval, does not invalidate the oDST.

Disclosure

Dr Carroll is an Editorial Board Member of this journal and was not involved in the editorial review or the decision to publish this article. Dr Nerenz receives research funding from Abbott Laboratories.

Acknowledgment

The authors thank the personnel at Wisconsin Diagnostic Laboratories for their work to develop and implement the Reflex Testing protocol. J.D.K. is a recipient of the 2024 Research Experience for Graduate and Medical Students (REGMS) award from the Endocrine Society (US).

References

Filed under: Cushing's, Diagnostic Testing | Tagged: , , , , | Leave a comment »

A Case 0f Hailey–Hailey Disease Accompanied by Cushing’s Syndrome and Adrenal Insufficiency Due to Long-Term Usage of Topical Steroids With Review of Literature

Posted on August 14, 2025 by MaryO
Abstract

Hailey–Hailey disease (HHD), or familial benign chronic pemphigus, is a rare autosomal dominant disorder characterized by recurrent vesicles and erosions in intertriginous areas. Topical corticosteroids are the primary treatment, but their potential systemic side effects are often overlooked. Prolonged use on compromised skin can lead to excessive absorption, increasing the risk of iatrogenic Cushing’s syndrome and adrenal insufficiency.

Here, we report the case of a 50-year-old woman with HHD who had been using topical clobetasol or betamethasone for over 10 years, reaching doses up to 50 g/day.

She developed Cushingoid features, metabolic abnormalities, and suppression of the hypothalamic–pituitary–adrenal (HPA) axis. After tapering off topical corticosteroids, she developed adrenal insufficiency and associated withdrawal symptoms. Following the initiation of hydrocortisone replacement therapy, psychiatric symptoms, impaired glucose tolerance, and osteoporotic fractures emerged, suggesting exacerbation of iatrogenic Cushing’s syndrome.

This case highlights the risk of systemic complications from chronic topical corticosteroid use, particularly in high-absorption areas. Gradual dose reduction, close endocrine monitoring, and individualized tapering strategies are essential to prevent severe outcomes.

Clinicians should be aware of potential adrenal suppression and consider endocrine evaluation in patients receiving prolonged, high-dose topical corticosteroid therapy.

Filed under: adrenal, Cushing's, Rare Diseases | Tagged: , , , , , , | Leave a comment »

Cushing’s Syndrome in a Young Woman Due to Prolonged Betamethasone Nasal Drop Use

Posted on August 11, 2025 by MaryO

Abstract

Background

Cushing’s syndrome is an uncommon but serious condition caused by long-term exposure to elevated cortisol levels, which is usually iatrogenic in origin. Although systemic corticosteroids are the most frequent agents, the association of intranasal corticosteroids with this condition is remarkably rare.

Case presentation

This report is about a 21-year-old Iranian woman using betamethasone nasal drops for nasal obstruction. The patient presented with weight gain, Amenorrhea, mood disturbances, red purplish striae, and mild hirsutism. Hormonal assessments revealed suppression of the hypothalamic–pituitary–adrenal axis.

Conclusion

This case demonstrates the underappreciated systemic effects of intranasal betamethasone to induce Cushing’s syndrome. It serves as a pivotal reminder of the need for vigilance in prescribing practices and reinforces the importance of early diagnosis to ensure favorable patient outcomes.

Peer Review reports

Background

Iatrogenic Cushing’s syndrome (CS) is an endocrine disease caused by long-term or high-dose glucocorticoid use [1]. Although iatrogenic cases are commonly associated with oral or injectable glucocorticoids [2], few reports described CS after the use of intranasal steroid sprays (INS) such as betamethasone in adults [3,4,5,6,7]. Currently, INS is widely used for managing conditions such as allergic rhinitis, nasal polyposis, and other upper airway disorders owing to their localized effects and limited systemic absorption [8, 9]. However, prolonged use, high doses, or using potent formulations can lead to significant systemic absorption, resulting in Hypothalamic–pituitary–adrenal (HPA) axis suppression, and frank CS [10]. Betamethasone nasal spray, a cornerstone in the treatment of nasal congestion, has the potential for systemic absorption by the nasal mucosa, particularly with prolonged or excessive use [11].

This report presents the case of a young woman who developed CS following the overuse of betamethasone nasal drops. It also highlights the importance of detailed patient histories when diagnosing CS and highlights the critical need to educate patients on the proper use and potential risks of steroid therapies to prevent complications. This case report adheres to the case report (CARE) guidelines [12].

Case presentation

This is the case of a 21-year-old Iranian female who presented with a history of rapid weight gain (30 kg in 8 months), irregular menstrual cycles, and significant mood changes. Her body mass index (BMI) was calculated at 40.07 kg/m2, classifying her as obese, and her blood pressure was recorded at 115/75 mmHg. In addition, she exhibited red–purple striae on her abdomen and limbs and mild hirsutism (modified Ferriman–Gallwey Score (FGS) score = 10), prompting admission for further evaluation after multiple outpatient visits yielded no definitive diagnosis.

Figure 1 is a clinical photograph (with patient consent) or an illustration of the red–purple striae.

Fig. 1

figure 1

Clinical photograph showcasing the red–purplish striae on the patient’s abdomen, arms, and lower limbs

Upon admission, the patient’s history revealed prolonged use of betamethasone 0.1% 1 mg/mL nasal drops, administered at a daily dosage of 5 cc, in combination with oxymetazoline (a sympathomimetic nasal preparation) at a daily dosage of 1 cc, over approximately 12 months, to address nasal obstruction. Her symptoms began 6 months after starting the nasal drops. Further medication history revealed no other corticosteroid use. Notably, the patient had a past diagnosis of polycystic ovary (PCO) syndrome made on the basis of Rotterdam 2003 criteria (oligomenorrhea since menarche and clinically androgen excess) but did not undergo treatment or maintain laboratory records.

A detailed hormonal evaluation was undertaken. Morning plasma cortisol less than 0.05 µg/dL and adrenocorticotropic hormone (ACTH) less than 5 (10–56 pg/mL) measurements were abnormally low. Her 24-hour urine-free cortisol concentrations of 1.04 µg/24 h were significantly reduced, indicating suppression of the HPA axis secondary to prolonged exogenous corticosteroid exposure. All tests were repeated several times by endocrinologists during the time course of disease manifestations.

Table 1 summarizes the hormonal test results to clearly display the abnormalities.

Table 1 Hormonal and biochemical test results with reference values

Imaging studies before admission included a computed tomography (CT) scan of the adrenal glands, which showed that both adrenal glands were of normal size. However, a dynamic pituitary magnetic resonance imaging (MRI) revealed an 11 mm pituitary gland, despite there being no rationale for imaging studies in this scenario.

The patient was counseled extensively about the condition, and betamethasone nasal drops were discontinued immediately. Ear, nose, and throat (ENT) consultation revealed normal findings and the psychiatric team diagnosed her with major depressive disorder (MDD). She was discharged on 15 mg prednisolone with a structured tapering plan to allow for gradual recovery of adrenal function and to prevent acute adrenal insufficiency. Follow-up appointments were scheduled to monitor her clinical progress and re-evaluate her HPA axis recovery.

Discussion

This case highlights the rare but significant occurrence of iatrogenic CS secondary to prolonged use of intranasal betamethasone. Although oral corticosteroids are well-known to cause HPA axis suppression, INS is generally considered safer owing to their localized effects and lowering systemic absorption side effects. However, the associated potential of systemic absorption in INS remains a concern [13]. As demonstrated in this case, prolonged use of potent formulations such as betamethasone can lead to significant systemic effects, particularly when administered inappropriately or at high doses.

Betamethasone nasal drops, although effective for treating nasal congestion and inflammation [14, 15], carry a potential risk of systemic absorption through the nasal mucosa. Factors, such as prolonged use [6, 16, 17], and high potency [18], can significantly increase systemic bioavailability. R. J. Perry et al. [19] in study of seven children highlights that even patients receiving doses within conventional safety ranges may exhibit varying sensitivity to glucocorticoids, leading to symptomatic adrenal suppression or glucocorticoid excess. Unlike newer corticosteroid compounds, such as fluticasone or mometasone, which undergo extensive first-pass metabolism in the liver, betamethasone exhibits minimal hepatic metabolism, contributing to its prolonged systemic activity [20, 21]. This pharmacokinetic profile underscores the need for careful regulation and monitoring of its use, even in ostensibly localized therapies.

The clinical manifestations in this patient, including central obesity, striae, hirsutism, and mood changes, were classic features of CS and guided the diagnostic process [22]. Scutelnicu et al. [23] reported a case of a patient in the second trimester of pregnancy who, owing to chronic sinusitis, underwent intranasal betamethasone spray therapy. The patient manifested extensive striae on the lower limbs, as well as edema in the legs, arms, and face, accompanied by a weight gain of 22 kg over 3 months. After switching the patient’s treatment to an alpha-1 adrenergic agonist spray, the condition was managed uneventfully without any symptoms of adrenal insufficiency.

Requesting imaging assessments, including a CT scan and MRI, as a first step further complicated the diagnostic process. This highlights a common diagnostic pitfall: the use of imaging as an initial approach can lead to the discovery of incidentalomas, which may misdirect clinical attention. Such findings risk overshadowing the primary etiology of the condition, potentially resulting in misdiagnosis or delayed treatment. This emphasizes the importance of prioritizing functional assessments over imaging in the early diagnostic workup to avoid unwarranted diagnostic confusion and ensure accurate identification of the underlying pathology.

Management involved the immediate cessation of betamethasone nasal drops and initiation of a structured tapering regimen with prednisolone to support adrenal recovery. The importance of stress-dose precautions during intercurrent illnesses was emphasized, alongside comprehensive patient education to prevent future misuse of corticosteroids. The gradual improvement in adrenal function during follow-up highlights the reversibility of glucocorticoid-induced adrenal suppression with appropriate intervention.

Conclusion

This case underscores several critical lessons. First, it emphasizes the importance of heightened awareness among healthcare providers regarding the potential systemic effects of topical corticosteroids, particularly potent formulations such as betamethasone. Second, it highlights the need for thorough history-taking and detailed patient education to prevent corticosteroid misuse. This report contributes to the limited body of literature on iatrogenic CS from intranasal corticosteroids, particularly in adults. Documenting the clinical presentation, diagnostic challenges, and successful management of this case, provides valuable insights into preventing, recognizing, and treating similar cases. It serves as a reminder of the delicate balance between therapeutic benefit and potential harm in corticosteroid therapy and advocates for ongoing research to establish safer prescribing practices.

Data availability

The data analyzed and generated in this study can be accessed through the corresponding author upon reasonable request.

Abbreviations

CS:
Cushing’s syndrome
INS:
Intranasal corticosteroids
HPA axis:
Hypothalamic–pituitary–adrenal axis
BMI:
Body mass index
FGS:
Ferriman–Gallwey Score
PCO:
Polycystic ovary
ACTH:
Adrenocorticotropic hormone
CT:
Computed tomography
MRI:
Magnetic resonance imaging
ENT:
Ear, nose, and throat
MDD:
Major depressive disorder

References

  1. Cristante J, Chabre O. Factitious, or iatrogenic but unexpected Cushing’s syndrome. Ann Endocrinol (Paris). 2023;84(3):370–2.

    PubMed Google Scholar

  2. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996):913–27.

    CAS PubMed Google Scholar

  3. Scutelnicu A, Panaitescu AM, Ciobanu AM, Gica N, Botezatu R, Peltecu G, et al. Iatrogenic cushing’s syndrome as a consequence of nasal use of betamethasone spray during pregnancy. Acta Endocrinol. 2020;16(4):511–7.

    CAS Google Scholar

  4. Sakamoto M, Morita K, Okamura E, Uchino T, Okamoto K, Ozawa Y, et al. A case of iatrogenic cushing syndrome due to overuse of nasal steriod and concurrent administration of clarithromycin. Teikyo Med J. 2018;41(4):161–8.

    Google Scholar

  5. Nutting CM, Page SR. Iatrogenic Cushing’s syndrome due to nasal betamethasone: a problem not to be sniffed at! Postgrad Med J. 1995;71(834):231–2.

    CAS PubMed PubMed Central Google Scholar

  6. Stevens DJ. Cushing’s syndrome due to the abuse of betamethasone nasal drops. J Laryngol Otol. 1988;102(3):219–21.

    CAS PubMed Google Scholar

  7. Dow A, Yu R, Carmichael J. Too little or too much corticosteroid? Coexisting adrenal insufficiency and Cushing’s syndrome from chronic, intermittent use of intranasal betamethasone. Endocrinol Diabetes Metab Case Rep. 2013;2013:13–0036.

    Google Scholar

  8. Bachert C, Desrosiers MY, Hellings PW, Laidlaw TM. The role of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9(3):1099–106.

    CAS PubMed Google Scholar

  9. Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36.

    CAS PubMed Google Scholar

  10. Quddusi S, Browne P, Toivola B, Hirsch IB. Cushing syndrome due to surreptitious glucocorticoid administration. Arch Intern Med. 1998;158(3):294–6.

    CAS PubMed Google Scholar

  11. Grayson JW, Harvey RJ. Topical corticosteroid irrigations in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(S1):S9–15.

    PubMed Google Scholar

  12. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Global Adv Health Med. 2013;2(5):38–43.

    Google Scholar

  13. McDonnell J, Weller K, Pien LC. Safety of intranasal steroids: an updated perspective. Curr Allergy Asthma Rep. 2020;20(11):69.

    PubMed Google Scholar

  14. Scadding GK. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Allergy. 2000;55(s62):19–23.

    PubMed Google Scholar

  15. Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4(4):Cd011993.

    PubMed Google Scholar

  16. Findlay CA, Macdonald JF, Wallace AM, Geddes N, Donaldson MD. Childhood Cushing’s syndrome induced by betamethasone nose drops, and repeat prescriptions. BMJ. 1998;317(7160):739–40.

    CAS PubMed PubMed Central Google Scholar

  17. Reynolds C, Agrawal P, McCann A, O’Sullivan T, Chroinin MN, O’Riordan SMP. Cushing syndrome and adrenal insufficiency induced by high dose prolonged intranasal betamethasone. Arch Dis Child. 2019;104:A275.

    Google Scholar

  18. Oluwayemi IO, Oduwole AO, Oyenusi E, Onyiriuka AN, Abdullahi M, Fakeye-Udeogu OB, et al. Iatrogenic Cushing’s syndrome in children following nasal steroid. Pan Afr Med J. 2014;17:237.

    PubMed PubMed Central Google Scholar

  19. Perry RJ, Findlay CA, Donaldson MDC. Cushing’s syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child. 2002;87(1):45–8.

    CAS PubMed PubMed Central Google Scholar

  20. Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulm Pharmacol Ther. 2019;58: 101828.

    CAS PubMed Google Scholar

  21. Krzyzanski W, Milad MA, Jobe AH, Peppard T, Bies RR, Jusko WJ. Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. J Pharmacokinet Pharmacodyn. 2021;48(2):261–72.

    CAS PubMed PubMed Central Google Scholar

  22. Savas M, Mehta S, Agrawal N, van Rossum EFC, Feelders RA. Approach to the patient: diagnosis of Cushing syndrome. J Clin Endocrinol Metab. 2022;107(11):3162–74.

    PubMed PubMed Central Google Scholar

  23. Scutelnicu A, Panaitescu AM, Ciobanu AM, Gica N, Botezatu R, Peltecu G, et al. Iatrogenic Cushing’s syndrome as a consequence of nasal use of betamethasone spray during pregnancy. Acta Endocrinol (Buchar). 2020;16(4):511–7.

    CAS PubMed Google Scholar

Download references

Acknowledgements

Not applicable.

Funding

Not Applicable.

Author information

Authors and Affiliations

  1. Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran

    Mohammadsadra Shamohammadi

  2. M.D., Endocrinologist Assistant Professor of Internal Medicine Assistant Professor of Internal Medicine, Iran University of Medical Sciences at Rasool Akram General Hospital, Tehran, Iran

    Delaram Eskandari

  3. Professor of Endocrinology Department of Endocrinology, Rasool Akram Medical Complex, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    Amir Ziaee

  4. Assistant Professor of Endocrinology & Metabolism Department of Internal Medicine, School of Medicine Hazrat-e Rasool General Hospital Iran University of Medical Sciences Medical Doctor at Iran University of Medical Sciences, Tehran, Iran

    Seyed Hossein Samadanifard

  5. Assistant Professor of Endocrinology & Metabolism Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    Haleh Chehrehgosha

  6. M.D., Endocrinologist Assistant Professor of Internal Medicine Assistant Professor of Internal Medicine, Iran University of Medical Sciences at Rasool Akram General Hospital, Tehran, Iran

    Amir Hossein Ghanooni

Contributions

MS and DE wrote the original draft; AZ and SHS collected the data. DE and HC were the patient’s doctors; MS and AHG reviewed, edited, and supervised the manuscript. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Delaram Eskandari.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with ethical guidelines and was approved by the Research Ethics Committee of Iran University of Medical Sciences under approval number IR.IUMS.REC.1404.208.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Filed under: adrenal crisis, Cushing's, Rare Diseases | Tagged: , , , , , , , , , | Leave a comment »

Cushing Syndrome Leaves Lasting Health Effects

Posted on August 8, 2025 by MaryO

TOPLINE:

Compared with a matched population-based control group, patients with Cushing syndrome continued to exhibit elevated systolic and diastolic blood pressures along with reduced kidney function at least 14 years after biochemical remission.

METHODOLOGY:

  • Researchers in Germany conducted a retrospective cohort study to assess the long-term trajectory of blood pressure and kidney function in patients who achieved remission of Cushing syndrome.
  • They included 81 patients with Cushing syndrome (median age at baseline, 44 years; 75.3% women) and compared them with 243 matched control individuals from a population-based cohort.
  • Data were collected before treatment at baseline and at median follow-up intervals of 7.1 and 14 years after biochemical remission, with assessments of blood pressure, glomerular filtration rate, the prevalence of chronic kidney disease, and the use of antihypertensives.

TAKEAWAY:

  • Patients with Cushing syndrome had a significant reduction in blood pressure and required fewer antihypertensives at both 7 and 14 years vs baseline.
  • However, when compared with the control group, patients with Cushing syndrome had significantly elevated systolic and diastolic pressures at baseline and 7 and 14 years post-remission (P ≤ .0002 for all).
  • Although the proportion of patients on antihypertensive medications decreased in the Cushing syndrome group after remission was achieved, the prevalence of uncontrolled hypertension remained higher than in the control group at all follow-up points. In fact, reducing the use of these medications was associated with an increased risk for uncontrolled hypertension.
  • Kidney function assessed via glomerular filtration rate remained consistently lower among patients with Cushing syndrome than among control individuals at baseline and 7 and 14 years post-remission (P = .005, P < .0001, and P = .0359, respectively).

IN PRACTICE:

“Our findings provide further evidence that cardiovascular effects of hypercortisolism are not entirely reversible with the normalization of cortisol levels and enhance our understanding of the deteriorative long-term cardiovascular consequences of chronic hypercortisolism,” the authors wrote.

SOURCE:

This study was led by Katrin Ritzel, Ludwig-Maximilians-Universität München (LMU Munich), LMU University Hospital in Munich, Germany. It was published online on July 29, 2025, in Journal of Endocrinological Investigation.

LIMITATIONS:

The retrospective design and single-centre nature of this study could have been considered limitations.

DISCLOSURES:

This study was supported by Else Kröner-Fresenius Stiftung. Some authors reported being supported by Deutsche Forschungsgemeinschaft, the Munich Clinician Scientist Program, the Clinician Scientist Pro­gramme on Rare Important Syndromes in Endocrinology, and other sources. All authors reported having no conflicts of interest.

https://www.medscape.com/viewarticle/cushing-syndrome-leaves-lasting-health-effects-2025a1000kj0

Filed under: Cushing's, symptoms | Tagged: , , , | Leave a comment »

« Previous Page — Next Page »